The present of local manufacturers of collagen peptide and gelatin in developing countries has increased the competition for leading players at the regional level, reports Transparency Market Research in a new study. The comprehensive use of collagen peptide and gelatin accompanied with varied pricing strategies has amplified the competitive rivalry among market players. The top three companies in the collagen peptide market, Rousselot International, GELITA AG, and Roxlor LLC account for nearly 57% of the overall global share. The global gelatin market is dominated by GELITA AG, PB Gelatin, and Rousselot International as they account for nearly 65% of the global share.
Obtain the Upcoming Market Trends of Collagen Peptide and Gelatin at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1070
Due to the increasing competition in developing countries, leading companies are investing on research and development studies associated with novel drug delivery systems, which is in turn aiding the application of collage peptide and gelatin. To avoid barriers of religion and regulatory organizations, the development of non-animal origin collagen peptide and gelatin is expected to provide manufacturers of collagen peptide and gelatin with growth prospects.
Growth of Wound Healing and Regenerative Medicine Segment to Provide Growth Opportunities to Collagen Peptide Manufacturers
According to the TMR report, the wound healing and regenerative medicine segment is projected to grow at a substantial rate in the upcoming years. This segment is expected to maintain a good market position due to government funding, increasing cases of diabetes, and upsurge in global obese and geriatric population. As regenerative medicines have collagen peptide as additives in their formulation, the manufacturers of collagen peptide are looking forward to capitalize this opportunity.
The major pharmaceutical and biotechnology companies are focusing on the development of the regenerative technology by creating a favorable environment for the quality enhancement of these technologies. The most lucrative market for regenerative medicine is considered to be Asia-Pacific with India and China leading on the front. The emerging countries are expected to provide growth opportunities to the manufacturers of collagen peptide as they are expected to be the potential markets for wound healing applications.
Use of Bovine and Porcine Sources likely to Restrain Demand for Gelatin and Collagen Peptide
As bovine-derived gelatin and collagen peptide is cow derivative, it can act as a carrier of a neurodegenerative disease commonly known as mad cow disease. For instance, in October 2009 166 people died in the U.K. due to the inclusion of animals infected with Bovine Spongiform Encephalopathy into the human food chain. Many developed countries have imposed strict regulations on the import of animal derivative materials due to the risk of diseases being communicated through them. Bovine and porcine are the most commonly used sources in the formulation of collagen peptide and gelatin, thus inhibiting the demand for gelatin and collagen peptide.
Varied cultural and religious restrictions regarding the use of gelatin and collagen peptide products due to their animal derivative nature are likely to hinder the growth of the global collagen peptide and gelatin market. In this regard, the presence of substitutes such as vegetable gelatin is expected to pose a great threat to the collagen peptide and gelatin market.
In spite of the drawbacks, the global collagen peptide market is anticipated to grow at CAGR of 6.8% and the global gelatin market is expected to rise at a significant CAGR of 7.5% during 2014 and 2020. The global collagen peptide market is estimated to have a worth of US$1.1 bn with gelatin market to be valued at US$3.0 bn by 2020. North America is projected to lead the global collagen peptide market with a revenue of USD$380.0 mn by 2020. The gelatin market is expected to be dominated by Europe with a market worth of US$1.1 bn by the end of 2020.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453